These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38132385)

  • 21. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
    McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
    Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1293-1304. PubMed ID: 36285641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
    Agarwal N; Azad AA; Carles J; Fay AP; Matsubara N; Heinrich D; Szczylik C; De Giorgi U; Young Joung J; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Lin X; Healy CG; Di Santo N; Zohren F; Fizazi K
    Lancet; 2023 Jul; 402(10398):291-303. PubMed ID: 37285865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Chao Z; Wang Z; Li L; Jiang Y; Tang Y; Wang Y; Hao X; Zhang C; Guo X; Yu W; Cheng F; Wang Z
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138301
    [No Abstract]   [Full Text] [Related]  

  • 27. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
    Higano CS; Cheng HH
    Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
    Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
    Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer.
    Chen X; Pan Y; Wang Q; Ren C; Li M; Hao X; Xie L; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1225033. PubMed ID: 38027160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing.
    Triner D; Graf RP; Madison RW; Gjoerup O; Tukachinsky H; Ross JS; Quintanilha JCF; Li G; Cheng HH; Pritchard CC; Zurita AJ; Qin Q; Zhang T; Agarwal N; Reichert ZR; Mateo J; Cieslik M; Morgan TM
    ESMO Open; 2024 Sep; 9(9):103684. PubMed ID: 39255537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].
    Heidegger I; Becker C; Tsaur I; Todenhöfer T;
    Urologe A; 2022 Feb; 61(2):187-192. PubMed ID: 35013792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.
    Akbıyık I; Ürün Y
    Future Oncol; 2023 Dec; 19(39):2585-2591. PubMed ID: 38073492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
    Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    Simmons AD; Nguyen M; Pintus E
    BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?
    VanderWeele DJ; Hussain M
    NEJM Evid; 2022 Sep; 1(9):EVIDe2200154. PubMed ID: 38319811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
    Clin Transl Oncol; 2024 Oct; 26(10):2559-2571. PubMed ID: 38750344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.